CHRIS GETMAN — Lobbyist Profile | Poliscope

CHRIS GETMAN

Filings

Clients

Firms

Years active

2022–2026

Associated filing income

$780,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	17	2022–2026
WE WORK FOR HEALTH	3	2022

Lobbying firms

Firm	Filings	Years
BRAVO GROUP	20	2022–2026

Original LDA source filings (20)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2026 · second_quarter · Q2

Firm income: $30,000

Source: Senate LDA

Show 16 more original filings

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2025 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2025 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2025 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2024 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2024 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2024 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2024 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2023 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2023 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2023 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2023 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

WE WORK FOR HEALTH via BRAVO GROUP

2022 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Biopharmaceutical advocacy and educational outreach.

MED

Medical/Disease Research/Clinical Labs

Biopharmaceutical advocacy and educational outreach.

HCR

Health Issues

Biopharmaceutical advocacy and educational outreach.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

WE WORK FOR HEALTH via BRAVO GROUP

2022 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MED

Medical/Disease Research/Clinical Labs

Biopharmaceutical advocacy and educational outreach.

MMM

Medicare/Medicaid

Biopharmaceutical advocacy and educational outreach.

HCR

Health Issues

Biopharmaceutical advocacy and educational outreach.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2022 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

WE WORK FOR HEALTH via BRAVO GROUP

2022 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Biopharmaceutical advocacy and educational outreach.

MED

Medical/Disease Research/Clinical Labs

Biopharmaceutical advocacy and educational outreach.

HCR

Health Issues

Biopharmaceutical advocacy and educational outreach.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP

2022 · third_quarter · Q3

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE